Stallergenes Signs an Exclusive Partnership Agreement With Solvay Pharmaceuticals for the Promotion and Distribution of its Products in Russia and the CIS*
Solvay Pharmaceuticals Marketing and Licensing AG (subsidiary of Solvay
Group) announce the signing of an exclusive partnership agreement for the
promotion and distribution of Stallergenes diagnostic and treatment products
in
With an estimated 20 million allergy sufferers and a strong demand on the
part of the medical community for quality products, the Russian market
represents a real opportunity for Stallergenes.
The main products in Stallergenes’ injectable and sublingual ranges will
soon be the subject of registration applications. This partnership will
enable Stallergenes to meet more than 80% of the needs of allergy sufferers
in
“We’re delighted to be teaming up with Solvay Pharmaceuticals to target
the potential growth this new market represents. Thanks to its franchise and
its considerable expertise recognized by allergy specialists, Solvay
Pharmaceuticals will enable us to promote the desensitization standardized
products, and notably the sublingual route, and their benefits for patients,”
declared
“We’re tremendously enthusiastic about the prospect of collaborating with
the world leader in sublingual desensitization therapy and making its
innovative standardized products available to practitioners,” emphasizes Mr.
*countries concerned:
States:
About Stallergenes’ International Development
Today, Stallergenes markets its products in more than 50 different
countries, via 11 subsidiaries throughout
and partnership agreements around the globe.
To help it pursue its development in new markets, Stallergenes is
supported by unique expertise and the responsiveness of its structure. In
high-potential emerging markets such as
tailored product offer strategy, working with partners closely involved in
the field of respiratory allergy treatment.
In the last five years, five new subsidiaries have been opened in
and several partnership agreements have been signed.
About Stallergenes
Stallergenes is a European biopharmaceutical company dedicated to
desensitization therapies for the prevention and treatment of allergy-related
respiratory diseases, such as rhinoconjunctivitis and allergic asthma. A
pioneer and leader in sublingual desensitization treatments, Stallergenes
devotes 21% of its turnover, in gross terms, to Research and Development and
is actively involved in the development of a new therapeutic class:
sublingual desensitization tablets.
In 2008, Stallergenes had a turnover of
500,000 patients were treated with Stallergenes desensitization products.
Stallergenes is listed on Euronext Paris (Compartment B and is part of
the sample composing the SBF 120 index.
ISIN code: FR0000065674
Reuters code: GEN.PA
Bloomberg code: GEN.FP
Additional information is available at http://www.stallergenes.com
About Solvay Pharmaceuticals
Solvay Pharmaceuticals is a research driven group of companies that
constitutes the global pharmaceutical business of the Solvay Group. These
companies seek to fulfill carefully selected, unmet medical needs in the
therapeutic areas of neuroscience, cardiometabolic, influenza vaccines,
gastroenterology and men’s and women’s health. Its 2008 sales were
billion
information, visit http://www.solvaypharmaceuticals.com.
SOLVAY GROUP is an international chemical and pharmaceutical Group with
headquarters in
In 2008, its consolidated sales amounted to
three sectors of activity: Chemicals, Plastics and Pharmaceuticals. Solvay is
listed on the NYSE Euronext stock exchange in
SOLB.BE – Bloomberg: SOLB.BB – Reuters: SOLBt.BR). Details are available at
http://www.solvay.com.
SOURCE Stallergenes